TMCnet News
Agios Announces Closing of Public OfferingCAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq:AGIO) today announced the closing of its previously announced underwritten public offering of 5,050,505 shares common stock at the public offering price of $49.50 per share, resulting in gross proceeds of approximately $250 million. The underwriters have until May 18, 2017 to exercise their option to purchase from Agios up to an additional 15% of the shares of common stock offered in the public offering on the same terms and conditions. J.P. Morgan Securities LLC and Goldman, Sachs & Co. acted as joint book-running managers for the offering. Cowen and Company, LLC served as lead manager. The shares were offered by Agios pursuant to an automatically effective shelf registration statement that was previously filed with the Securities and Exchange Commission (“SEC”). A prospectus supplement relating to, and describing the terms of, the offering has been filed with the SEC and is available on the SEC’s web site at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering can be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, telephone: 866-803-9204; or Goldman, Sachs, & Co., Attn: Prospectus Department, 200 West Street, New York, New York 10282, telephone: 866-471-2526, facsimile: 212-902-9316, e-mail: [email protected]. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Agios Pharmaceuticals, Inc. Cautionary Note Regarding Forward Looking Statements Kendra Adams, Senior Director, Investor & Public Relations [email protected] 617-844-6407 Renee Leck, Senior Manager, Investor & Public Relations [email protected] 617-649-8299 |